{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:47:17Z","timestamp":1792432037388,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"crossref","award":["Ricerca Corrente 860\/01\/2023"],"award-info":[{"award-number":["Ricerca Corrente 860\/01\/2023"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00408-024-00768-1","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T04:08:04Z","timestamp":1732939684000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Lung Clearance Index Improves in People with Cystic Fibrosis not Achieving a Clinical Important Difference in Forced Expiratory Volume in One Second After Elexacaftor\/Tezacaftor\/Ivacaftor Therapy"],"prefix":"10.1007","volume":"203","author":[{"given":"Valeria","family":"Dacc\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gramegna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rosazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Biffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Lanfranchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Zazzeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Bellante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0430-2714","authenticated-orcid":false,"given":"Gianfranco","family":"Alicandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,30]]},"reference":[{"key":"768_CR1","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1056\/NEJMOA0909825","volume":"363","author":"FJ Accurso","year":"2010","unstructured":"Accurso FJ, Rowe SM, Clancy JP et al (2010) Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363:1991\u20132003. https:\/\/doi.org\/10.1056\/NEJMOA0909825","journal-title":"N Engl J Med"},{"key":"768_CR2","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman HGM, McKone EF, Downey DG et al (2019) Efficacy and safety of the elexacaftor\/tezacaftor\/ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet (London, England) 394:1940. https:\/\/doi.org\/10.1016\/S0140-6736(19)32597-8","journal-title":"Lancet (London, England)"},{"key":"768_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/IJMS21165882","volume":"21","author":"A Gramegna","year":"2020","unstructured":"Gramegna A, Contarini M, Aliberti S et al (2020) From ivacaftor to triple combination: a systematic review of efficacy and safety of CFTR modulators in people with cystic fibrosis. Int J Mol Sci 21:1\u201323. https:\/\/doi.org\/10.3390\/IJMS21165882","journal-title":"Int J Mol Sci"},{"key":"768_CR4","unstructured":"Zolin A, Orenti A, Jung A, et al (2023) European Cystic Fibrosis Society Patient Registry (ECFSPR) - Annual Report 2021. www.ecfs.eu\/ecfspr. Accessed 14 May 2024"},{"key":"768_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/J.LANEPE.2023.100690","author":"S Sutharsan","year":"2023","unstructured":"Sutharsan S, Dillenhoefer S, Welsner M et al (2023) Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry. Lancet Reg Heal Eur. https:\/\/doi.org\/10.1016\/J.LANEPE.2023.100690","journal-title":"Lancet Reg Heal Eur"},{"key":"768_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000001338","author":"SW Chun","year":"2024","unstructured":"Chun SW, Somers ME, Burgener EB (2024) Highly effective cystic fibrosis transmembrane conductance (regulator) modulator therapy: shifting the curve for most while leaving some further behind. Curr Opin Pediatr. https:\/\/doi.org\/10.1097\/MOP.0000000000001338","journal-title":"Curr Opin Pediatr"},{"key":"768_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/J.JCF.2023.02.004","volume":"22","author":"A Lopez","year":"2023","unstructured":"Lopez A, Daly C, Vega-Hernandez G et al (2023) Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del. J Cyst Fibros 22:607\u2013614. https:\/\/doi.org\/10.1016\/J.JCF.2023.02.004","journal-title":"J Cyst Fibros"},{"key":"768_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2021-000998","author":"K Bresnick","year":"2021","unstructured":"Bresnick K, Arteaga-Solis E, Millar SJ et al (2021) Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies. BMJ Open Respir Res. https:\/\/doi.org\/10.1136\/bmjresp-2021-000998","journal-title":"BMJ Open Respir Res"},{"key":"768_CR9","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman HGM, McKone EF, Downey DG et al (2019) Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet (London, England) 394:1940\u20131948. https:\/\/doi.org\/10.1016\/S0140-6736(19)32597-8","journal-title":"Lancet (London, England)"},{"key":"768_CR10","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMOA1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P et al (2019) Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 381:1809\u20131819. https:\/\/doi.org\/10.1056\/NEJMOA1908639","journal-title":"N Engl J Med"},{"key":"768_CR11","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1164\/RCCM.202102-0509OC","volume":"203","author":"ET Zemanick","year":"2021","unstructured":"Zemanick ET, Taylor-Cousar JL, Davies J et al (2021) A phase 3 open-label study of Elexacaftor\/Tezacaftor\/Ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele. Am J Respir Crit Care Med 203:1522\u20131532. https:\/\/doi.org\/10.1164\/RCCM.202102-0509OC","journal-title":"Am J Respir Crit Care Med"},{"key":"768_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2024.04.013","author":"G Alicandro","year":"2024","unstructured":"Alicandro G, Gramegna A, Bellino F et al (2024) Heterogeneity in response to Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis. J Cyst Fibros. https:\/\/doi.org\/10.1016\/j.jcf.2024.04.013","journal-title":"J Cyst Fibros"},{"key":"768_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2024.03.033","author":"A Gramegna","year":"2024","unstructured":"Gramegna A, Alicandro G, Premuda C et al (2024) Relationship between lung volumes and heterogeneity in the response to Elexacaftor\/Tezacaftor\/Ivacaftor in patients with cystic fibrosis and advanced lung disease. Chest. https:\/\/doi.org\/10.1016\/j.chest.2024.03.033","journal-title":"Chest"},{"key":"768_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/thx.2007.082768","volume":"63","author":"JC Davies","year":"2008","unstructured":"Davies JC, Cunningham S, Alton EWFW, Innes JA (2008) Lung clearance index in CF: a sensitive marker of lung disease severity. Thorax 63:96\u201397","journal-title":"Thorax"},{"key":"768_CR15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1164\/RCCM.201310-1863PP","volume":"189","author":"PW Jones","year":"2014","unstructured":"Jones PW, Beeh KM, Chapman KR et al (2014) Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 189:250\u2013255. https:\/\/doi.org\/10.1164\/RCCM.201310-1863PP","journal-title":"Am J Respir Crit Care Med"},{"key":"768_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1164\/rccm.202301-0021OC","volume":"208","author":"C Wainwright","year":"2023","unstructured":"Wainwright C, McColley SA, McNally P et al (2023) Long-term safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in children aged >6 years with cystic fibrosis and at least one F508del allele a phase 3, open-label clinical trial. Am J Respir Crit Care Med 208:68\u201378. https:\/\/doi.org\/10.1164\/rccm.202301-0021OC","journal-title":"Am J Respir Crit Care Med"},{"key":"768_CR17","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1542\/peds.23.3.545","volume":"23","author":"LE Gibson","year":"1959","unstructured":"Gibson LE, Cooke RE (1959) A test for concentration of electrolytes in sweat in cystic fibrosis of. Pediatrics 23:545\u2013549","journal-title":"Pediatrics"},{"key":"768_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0022-3476(94)70314-0","volume":"124","author":"KB Hammond","year":"1994","unstructured":"Hammond KB, Turcios NL, Gibson LE (1994) Clinical evaluation of the macroduct sweat collection system and conductivity analyzer in the diagnosis of cystic fibrosis. J Pediatr 124:255\u2013260. https:\/\/doi.org\/10.1016\/S0022-3476(94)70314-0","journal-title":"J Pediatr"},{"key":"768_CR19","unstructured":"Italian Cystic Fibrosis Society (SIFC) Sweat Test Working Group The Sweat Test: Recommendations for Proper Execution and Result Interpretation (Third Ed. April 2022). https:\/\/www.sifc.it\/wp-content\/uploads\/2022\/06\/Raccomandazioni-Italiane-sul-Test-del-Sudore-_Aprile-2022.pdf. Accessed 24 Nov 2023"},{"key":"768_CR20","doi-asserted-by":"publisher","first-page":"E70","DOI":"10.1164\/rccm.201908-1590ST","volume":"200","author":"BL Graham","year":"2019","unstructured":"Graham BL, Steenbruggen I, Barjaktarevic IZ et al (2019) Standardization of spirometry 2019 update an official American thoracic society and European respiratory society technical statement. Am J Respir Crit Care Med 200:E70\u2013E88. https:\/\/doi.org\/10.1164\/rccm.201908-1590ST","journal-title":"Am J Respir Crit Care Med"},{"key":"768_CR21","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1183\/09031936.00080312","volume":"40","author":"PH Quanjer","year":"2012","unstructured":"Quanjer PH, Stanojevic S, Cole TJ et al (2012) Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the global lung function 2012 equations. Eur Respir J 40:1324\u20131343. https:\/\/doi.org\/10.1183\/09031936.00080312","journal-title":"Eur Respir J"},{"key":"768_CR22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02398-2021","author":"AC Kentgens","year":"2022","unstructured":"Kentgens AC, Latzin P, Anagnostopoulou P et al (2022) Normative multiple-breath washout data in school-aged children corrected for sensor error. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.02398-2021","journal-title":"Eur Respir J"},{"key":"768_CR23","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00069712","author":"PD Robinson","year":"2013","unstructured":"Robinson PD, Latzin P, Verbanck S et al (2013) Consensus statement for inert gas washout measurement using multiple- and singlebreath tests. Eur Respir J. https:\/\/doi.org\/10.1183\/09031936.00069712","journal-title":"Eur Respir J"},{"key":"768_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157523","author":"R Jensen","year":"2016","unstructured":"Jensen R, Stanojevic S, Klingel M et al (2016) A systematic approach to multiple breath nitrogen washout test quality. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0157523","journal-title":"PLoS ONE"},{"key":"768_CR25","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/THX.2006.060889","volume":"62","author":"CH Goss","year":"2007","unstructured":"Goss CH, Burns JL (2007) Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax 62:360\u2013367. https:\/\/doi.org\/10.1136\/THX.2006.060889","journal-title":"Thorax"},{"key":"768_CR26","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1164\/RCCM.202202-0392OC","volume":"206","author":"MA Mall","year":"2022","unstructured":"Mall MA, Brugha R, Gartner S et al (2022) Efficacy and safety of Elexacaftor\/Tezacaftor\/Ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a phase 3b, randomized, placebo-controlled study. Am J Respir Crit Care Med 206:1361\u20131369. https:\/\/doi.org\/10.1164\/RCCM.202202-0392OC","journal-title":"Am J Respir Crit Care Med"},{"key":"768_CR27","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1164\/RCCM.202308-1317OC","volume":"208","author":"P McNally","year":"2023","unstructured":"McNally P, Lester K, Stone G et al (2023) Improvement in lung clearance index and chest computed tomography scores with Elexacaftor\/Tezacaftor\/Ivacaftor treatment in people with cystic fibrosis aged 12 years and older\u2014the recover trial. Am J Respir Crit Care Med 208:917\u2013929. https:\/\/doi.org\/10.1164\/RCCM.202308-1317OC","journal-title":"Am J Respir Crit Care Med"},{"key":"768_CR28","doi-asserted-by":"publisher","first-page":"2400004","DOI":"10.1183\/13993003.00004-2024","volume":"64","author":"M Stahl","year":"2024","unstructured":"Stahl M, Dohna M, Graeber SY et al (2024) Impact of elexacaftor\/tezacaftor\/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles. Eur Respir J 64:2400004. https:\/\/doi.org\/10.1183\/13993003.00004-2024","journal-title":"Eur Respir J"},{"key":"768_CR29","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S2213-2600(13)70182-6","volume":"1","author":"J Davies","year":"2013","unstructured":"Davies J, Sheridan H, Bell N et al (2013) Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. Lancet Respir Med 1:630\u2013638. https:\/\/doi.org\/10.1016\/S2213-2600(13)70182-6","journal-title":"Lancet Respir Med"},{"key":"768_CR30","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1164\/RCCM.200407-948OC","volume":"171","author":"R Kraemer","year":"2005","unstructured":"Kraemer R, Blum A, Schibler A et al (2005) Ventilation inhomogeneities in relation to standard lung function in patients with cystic fibrosis. Am J Respir Crit Care Med 171:371\u2013378. https:\/\/doi.org\/10.1164\/RCCM.200407-948OC","journal-title":"Am J Respir Crit Care Med"},{"key":"768_CR31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/thx.2006.062190","volume":"62","author":"PR Burgel","year":"2007","unstructured":"Burgel PR, Montani D, Danel C et al (2007) A morphometric study of mucins and small airway plugging in cystic fibrosis. Thorax 62:153\u2013161. https:\/\/doi.org\/10.1136\/thx.2006.062190","journal-title":"Thorax"},{"key":"768_CR32","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1164\/rccm.201507-1281OC","volume":"193","author":"M Boon","year":"2016","unstructured":"Boon M, Verleden SE, Bosch B et al (2016) Morphometric analysis of explant lungs in cystic fibrosis. Am J Respir Crit Care Med 193:516\u2013526. https:\/\/doi.org\/10.1164\/rccm.201507-1281OC","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-024-00768-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-024-00768-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-024-00768-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T04:42:11Z","timestamp":1766378531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-024-00768-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,30]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["768"],"URL":"https:\/\/doi.org\/10.1007\/s00408-024-00768-1","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,30]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.G., V.D. and F.B. reported honoraria for lectures from Vertex; A.G. reported honoraria for lectures from Zambon, Foodar, Insmed; F.B. reported honoraria for lectures from Viatris, Zambon, Foodar, Chiesi, Insmed; A.G. and V.D. reported travel support from Neupharma; A.G. and F.B. reported travel support from Viatris.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy (protocol number 594_2016).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Written informed consent was obtained from all individuals and their parents if the participant was under 18\u00a0years old.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}],"article-number":"9"}}